Literature DB >> 23154206

B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor.

Jonathan C Routh1, Paul E Grundy, James R Anderson, Alan B Retik, Kyle C Kurek.   

Abstract

PURPOSE: A minority of children with Wilms tumor will experience tumor recurrence. In a previous pilot study we found an association between expression of an immune costimulatory molecule, B7-H1, and tumor recurrence in favorable histology Wilms tumor. We sought to verify the prognostic value of B7-H1 as a biomarker in favorable histology Wilms tumor.
MATERIALS AND METHODS: We performed a nested case-control study of tumors from the Fifth National Wilms Tumor Study. We randomly selected 44 children unsuccessfully treated (cases) and 49 who were successfully treated for favorable histology Wilms tumor (controls). Cases and controls were matched based on tumor stage, and the analysis was restricted to children who underwent initial resection. We excluded patients with stage IV or V disease and those treated with chemotherapy or radiation. Tumor specimens were stained for B7-H1 expression.
RESULTS: Of the 93 total samples analyzed 60 (65%) demonstrated B7-H1 staining, with staining diffusely present in 13 (22%) and blastema predominant in 34 (57%). B7-H1 expression was associated with failure of initial therapy (p = 0.006). Patients with tumors showing less than 20% B7-H1 positive cells were at lower risk for treatment failure, while those with tumors exhibiting greater than 60% B7-H1 positive cells were at greater risk for treatment failure. This association appeared to be independent of tumor stage.
CONCLUSIONS: B7-H1 expression by favorable histology Wilms tumor is associated with an increased risk of failure of initial therapy.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23154206     DOI: 10.1016/j.juro.2012.11.012

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Biomarkers for Wilms Tumor: A Systematic Review.

Authors:  Eugene B Cone; Stewart S Dalton; Megan Van Noord; Elizabeth T Tracy; Henry E Rice; Jonathan C Routh
Journal:  J Urol       Date:  2016-05-31       Impact factor: 7.450

2.  Axl promotes the proliferation, invasion and migration of Wilms' tumor and can be used as a prognostic factor.

Authors:  Shibo Zhu; Guochang Liu; Wen Fu; Jinhua Hu; Kai Fu; Wei Jia
Journal:  Onco Targets Ther       Date:  2017-02-16       Impact factor: 4.147

3.  Competitive endogenous RNA (ceRNA) regulation network of lncRNAs, miRNAs, and mRNAs in Wilms tumour.

Authors:  Fucai Tang; Zechao Lu; Jiamin Wang; Zhibiao Li; Weijia Wu; Haifeng Duan; Zhaohui He
Journal:  BMC Med Genomics       Date:  2019-12-16       Impact factor: 3.063

4.  A Survival-Related Competitive Endogenous RNA Network of Prognostic lncRNAs, miRNAs, and mRNAs in Wilms Tumor.

Authors:  HengChen Liu; MingZhao Zhang; ManYu Shi; TingTing Zhang; ZeNan Zhang; QingBo Cui; ShuLong Yang; ZhaoZhu Li
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

5.  Identification of a ferroptosis-related lncRNA signature with prognosis for Wilms tumor.

Authors:  Hengchen Liu; Mingzhao Zhang; Tingting Zhang; Manyu Shi; Wenjun Lu; Shulong Yang; Qingbo Cui; Zhaozhu Li
Journal:  Transl Pediatr       Date:  2021-10

Review 6.  Pediatric Tumors-Mediated Inhibitory Effect on NK Cells: The Case of Neuroblastoma and Wilms' Tumors.

Authors:  Andrea Pelosi; Piera Filomena Fiore; Sabina Di Matteo; Irene Veneziani; Ignazio Caruana; Stefan Ebert; Enrico Munari; Lorenzo Moretta; Enrico Maggi; Bruno Azzarone
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.